{"groups":[{"description":"All subjects randomized to receive sipuleucel-T.\n\nAutologous peripheral blood mononuclear cells, including antigen presenting cells, that have been activated in vitro with a recombinant fusion protein, PAP-GM-CSF. Treatment consist of 3 doses administered approximately 2 weeks apart.","id":"FG000","title":"Sipuleucel-T"},{"description":"All subjects randomized to receive placebo.\n\nApproximately one-third of the autologous quiescent APCs prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"54"},{"groupId":"FG001","numSubjects":"40"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"Patient Refused to Continue"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Site Closure"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"82"},{"groupId":"FG001","numSubjects":"45"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"4"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"57"},{"groupId":"FG001","numSubjects":"41"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants were screened for evaluation of subject eligibility and performance of baseline tests/procedures.","recruitmentDetails":"Participants were randomized between January 2000 and September 2004 across 16 clinical trial sites."}